View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2017	Mar. 22, 2018	Jun. 30, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	CALADRIUS BIOSCIENCES, INC.
Entity Central Index Key	0000320017
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		9,552,653
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Public Float			$ 39,628,118

Consolidated Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current Assets
Cash and cash equivalents	$ 29,163,200	$ 7,076,651
Restricted cash	5,004,789	0
Marketable securities	25,916,681	0
Accounts receivable trade, net of allowance of $0 at December 31, 2017 and 2016, respectively	234,461	138,774
Prepaid and other current assets	790,514	1,900,493
Assets related to discontinued operations	0	15,533,043
Total current assets	61,109,645	24,648,961
Property, plant and equipment, net	256,905	705,438
Deferred tax assets	575,055	0
Other assets	1,434,077	1,582,209
Assets related to discontinued operations	0	26,577,834
Total assets	63,375,682	53,514,442
Current Liabilities
Accounts payable	1,343,089	2,226,580
Accrued liabilities	7,810,948	2,659,433
Long-term debt, current	0	3,126,457
Notes payable, current	159,180	563,777
Due to PCT	0	1,681,594
Liabilities related to discontinued operations	0	10,925,052
Total current liabilities	9,313,217	21,182,893
Notes payable	0	159,180
Long term debt	0	2,524,897
Other long-term liabilities	3,872,679	389,858
Liabilities related to discontinued operations	0	5,791,134
Total liabilities	13,185,896	30,047,962
Commitments and Contingencies
Redeemable Securities - Non-Controlling Interests	0	19,400,000
Stockholders' Equity
Preferred stock; authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 1 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at December 31, 2017 and December 31, 2016, respectively	100	100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 9,483,911 and 8,205,790 shares, at December 31, 2017 and December 31, 2016, respectively	9,484	8,206
Additional paid-in capital	433,044,209	410,372,049
Treasury stock, at cost; 11,080 shares at December 31, 2017 and December 31, 2016 respectively	(707,637)	(707,637)
Accumulated deficit	(381,810,109)	(404,788,809)
Accumulated other comprehensive loss	(27,978)	0
Total Caladrius Biosciences, Inc. stockholders' equity	50,508,069	4,883,909
Noncontrolling interests	(318,283)	(817,429)
Total equity	50,189,786	4,066,480
Liabilities and Equity, Total	$ 63,375,682	$ 53,514,442

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 0	$ 0
Preferred Stock
Preferred stock, shares authorized (shares)	20,000,000	20,000,000
Preferred stock, liquidation preference (shares)	1	1
Preferred stock, par value (USD per share)	$ 0.01	$ 0.01
Preferred stock, shares designated (shares)	825,000	825,000
Preferred stock, shares issued (shares)	10,000	10,000
Preferred stock, shares outstanding (shares)	10,000	10,000
Common Stock
Common stock, par value (USD per share)	$ 0.001	$ 0.001
Common stock, shares authorized (shares)	500,000,000	500,000,000
Common stock, shares, issued (shares)	9,483,911	8,205,790
Common stock, shares, outstanding (shares)	9,483,911	8,205,790
Treasury Stock
Treasury stock (shares)	11,080	11,080

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Research and development	$ 15,842,959	$ 16,699,213
General, and administrative	11,750,080	12,802,735
Operating expenses	27,593,039	29,501,948
Operating loss	(27,593,039)	(29,501,948)
Other income (expense):
Other income (expense), net	273,101	23,854
Interest expense	(377,768)	(1,779,657)
Other income (expense) total	(104,667)	(1,755,803)
Loss before benefit from income taxes and noncontrolling interests	(27,697,706)	(31,257,751)
Benefit from income taxes	(11,526,557)	0
Net loss from continuing operations	(16,171,149)	(31,257,751)
Discontinued operations - net	38,399,236	(2,051,782)
Net income (loss)	22,228,087	(33,309,533)
Less - net loss from continuing operations attributable to noncontrolling interests	(182,457)	(241,802)
Less - net loss from discontinued operations attributable to noncontrolling interests	(568,156)	(411,412)
Net income (loss) attributable to Caladrius Biosciences, Inc. common shareholders	22,978,700	(32,656,319)
Amounts Attributable to Caladrius Inc. common shareholders:
Loss from continuing operations	(15,988,692)	(31,015,949)
Income (loss) from discontinued operations - net of taxes	38,967,392	(1,640,370)
Net income (loss) attributable to Caladrius Biosciences, Inc. common shareholders	$ 22,978,700	$ (32,656,319)
Basic earnings (loss)
Continuing operations (USD per share)	$ (1.78)	$ (4.74)
Discontinued operations (USD per share)	4.34	(0.25)
Caladrius Biosciences, Inc. common shareholders (USD per share)	2.56	(4.99)
Diluted earnings (loss)
Continuing operations (USD per share)	(1.78)	(4.74)
Discontinued operations (USD per share)	4.34	(0.25)
Caladrius Biosciences, Inc. common shareholders (USD per share)	$ 2.56	$ (4.99)
Weighted average common shares outstanding:
Basic shares	8,968,954	6,548,251
Diluted shares	8,968,954	6,548,251

Consolidated Statements of Comprehensive Income (Loss) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 22,228,087	$ (33,309,533)
Other comprehensive loss:
Available for sale securities - net unrealized loss	(27,978)	(486)
Total other comprehensive loss	(27,978)	(486)
Comprehensive income (loss)	22,200,109	(33,310,019)
Comprehensive loss attributable to noncontrolling interests	(750,613)	(653,214)
Comprehensive income (loss) attributable to Caladrius Biosciences, Inc. common stockholders	$ 22,950,722	$ (32,656,805)

Consolidated Statements of Equity - USD ($)	Total	Total Caladrius Biosciences, Inc. Stockholders' Equity	Series B Convertible Preferred Stock	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Treasury Stock	Non- Controlling Interest in Subsidiary
Beginning Balance (in shares) at Dec. 31, 2015			10,000	5,673,302
Beginning Balance at Dec. 31, 2015	$ 23,283,824	$ 23,713,533	$ 100	$ 5,673	$ 396,547,401	$ 486	$ (372,132,490)	$ (707,637)	$ (429,709)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(33,309,533)	(32,656,319)					(32,656,319)		(653,214)
Unrealized loss on marketable securities	(486)	(486)				(486)
Share-based compensation (in shares)				114,344
Share-based compensation	(2,532,281)	(2,532,281)		$ (114)	(2,532,167)
Net proceeds from issuance of common stock (in shares)				2,418,144
Net proceeds from issuance of common stock	11,560,394	11,560,394		$ 2,419	11,557,975
Change in ownership in subsidiary	0	(265,494)			(265,494)				265,494
Ending Balance (in shares) at Dec. 31, 2016			10,000	8,205,790
Ending Balance at Dec. 31, 2016	4,066,480	4,883,909	$ 100	$ 8,206	410,372,049	0	(404,788,809)	(707,637)	(817,429)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	22,228,087	22,978,700					22,978,700		(750,613)
Unrealized loss on marketable securities	(27,978)	(27,978)				(27,978)
Share-based compensation (in shares)				54,545
Share-based compensation	(2,494,471)	(2,494,471)		$ (55)	(2,494,416)
Net proceeds from issuance of common stock (in shares)				1,219,741
Net proceeds from issuance of common stock	5,701,686	5,701,686		$ 1,219	5,700,467
Proceeds from option exercises (in shares)				3,835
Proceeds from option exercises	13,576	13,576		$ 4	13,572
Elimination of equity associated with PCT sale	(3,686,536)	0			0				(3,686,536)
Conversion of redeemable securities	19,400,000	14,733,908			14,733,908				4,666,092
Change in ownership in subsidiary	0	(270,203)			(270,203)				270,203
Ending Balance (in shares) at Dec. 31, 2017			10,000	9,483,911
Ending Balance at Dec. 31, 2017	$ 50,189,786	$ 50,508,069	$ 100	$ 9,484	$ 433,044,209	$ (27,978)	$ (381,810,109)	$ (707,637)	$ (318,283)

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net income (loss)	$ 22,228,087	$ (33,309,533)
(Income) loss from discontinued operations	(38,399,236)	2,051,782
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Equity-based compensation expense	1,963,202	1,773,691
Depreciation and amortization	372,001	450,266
Loss on disposal of assets	211,813	591,307
Income tax benefit	(11,526,557)	0
Deferred income taxes	(575,055)	0
Amortization/Accretion on marketable securities	339,964	0
Changes in operating assets and liabilities:
Prepaid and other current assets	1,109,979	457,390
Accounts receivable	(95,686)	(101,882)
Other assets	148,150	222,632
Due to PCT	1,681,593	(2,784,760)
Accounts payable, accrued liabilities and other liabilities	5,667,118	(3,145,758)
Net cash used in operating activities - continuing operations	(20,237,813)	(28,225,345)
Net cash (used in) provided by operating activities - discontinued operations	(638,069)	4,557,663
Net cash used in operating activities	(20,875,882)	(23,667,682)
Cash flows from investing activities:
Purchase of marketable securities	(60,158,123)	0
Sales of marketable securities	(33,873,500)	0
Proceeds from PCT sale	74,606,591	0
Net cash sold in PCT sale	(6,727,263)	0
Acquisition of property and equipment	(135,281)	(1,099,460)
Net cash provided by (used in) investing activities - continuing operations	41,459,424	(1,099,460)
Net cash used in investing activities - discontinued operations	(188,794)	(1,749,836)
Net cash provided by (used in) investing activities	41,270,630	(2,849,296)
Cash flows from financing activities:
Proceeds from exercise of options	13,576	0
Tax withholding payments on net share settlement equity awards	(357,666)	(72,010)
Net proceeds from issuance of capital stock	5,701,686	11,560,394
Repayment of long-term debt	(5,651,354)	(9,348,646)
Proceeds from notes payable	400,998	803,498
Repayment of notes payable	(964,776)	(1,030,351)
PCT dividend to Caladrius	0	15,000,000
Net cash (used in) provided by financing activities - continuing operations	(857,536)	16,912,885
Net cash (used in) provided by financing activities - discontinued operations	(74,231)	3,990,690
Net cash (used in) provided by financing activities	(931,767)	20,903,575
Net increase (decrease) in cash, cash equivalents and restricted cash	19,462,981	(5,613,403)
Cash and cash equivalents at beginning of year - continuing operations	7,076,651	18,657,971
Cash and cash equivalents at beginning of year - discontinued operations	7,628,357	1,660,440
Cash, cash equivalents and restricted cash at end of year	34,167,989	14,705,008
Less cash and cash equivalents of discontinued operations at end of year	0	7,628,357
Cash, cash equivalents and restricted cash of continuing operations at end of year	34,167,989	7,076,651
Supplemental Disclosure of Cash Flow Information:
Interest	711,901	1,823,424
Taxes	$ 0	$ 0

The Business	12 Months Ended
The Business	Dec. 31, 2017
The Business [Abstract]
The Business	The Business OVERVIEW Caladrius Biosciences, Inc. (“we,” “us,” "our," “Caladrius” or the “Company”) is a company developing cellular therapeutics to treat certain diseases. We leverage specialized development expertise to selectively advance therapeutic product candidates to their next significant development milestone and, if appropriate, partner such candidates. Our most advanced product candidate, CLBS03, is an autologous polyclonal regulatory T cell ("Treg") clinical phase 2 therapy targeting children aged 8-17 with recent-onset type 1 diabetes mellitus ("T1D"). We also have phase 2 studies either underway or due to commence shortly involving our CD34 cell therapy for ischemic repair. Immunomodulation (Treg Technology) We are developing strategically, through the utilization of our core development expertise, a product candidate (CLBS03) that has the potential to be an innovative therapy for T1D. This therapy is based on a proprietary platform technology for immunomodulation. We have selected as an initial target the unmet medical need of patients who are newly diagnosed with T1D, most of whom will be under the age of 18. This program is based on the use of Tregs to treat diseases caused by imbalances in an individual's immune system. This novel approach seeks to restore immune balance by enhancing Treg number and function. Tregs are a natural part of the human immune system and regulate the activity of effector T cells, the cells that are responsible for protecting the body from pathogens and foreign antigens. When Tregs function properly, only harmful foreign materials are attacked by effector T cells. In autoimmune disease, however, it is thought that deficient Treg activity and numbers permit the effector T cells to attack the body's own beneficial cells. In the case of T1D, the beta cells in the pancreas are attacked, thereby reducing and/or eliminating over time the patient's ability to produce insulin. Insulin is necessary to regulate sugar metabolism and maintain proper sugar levels in the blood. Inconsistent or unnatural insulin levels can lead to many complications, including blindness, vascular disease and, if no insulin supplement is provided, even death. There are currently no curative treatments for TID, only lifelong insulin therapy, which often does not prevent serious co-morbidities. Two Phase 1 clinical trials of Treg technology in T1D, taken together demonstrated safety and tolerance, feasibility of manufacturing, an implied durability of effect as well as an early indication of potential therapeutic effect through the preservation of beta cell function. In the first quarter of 2016, we commenced patient enrollment in the first of two cohorts in The Sanford Project: T-Rex Study, a Phase 2 prospective, randomized, placebo-controlled, double-blind clinical trial (the "TRex Study") to evaluate the safety and efficacy of CLBS03 in adolescents with recent onset TID. We entered into a strategic collaboration with Sanford Research to support the execution of this trial. Sanford Research is a U.S.-based non-profit research organization that supports an emerging translational research center focused on finding a cure for T1D. On February 23, 2017, the California Institute for Regenerative Medicine ("CIRM") awarded us funds of up to $12.2 million to support the T-Rex Study. The funding will be based upon the achievement of certain milestones related to the proportion of subjects enrolled in California, as well as manufacturing and development costs incurred in California. We received $5.7 million in initial funding on May 4, 2017. CLBS03 has been granted Fast Track and orphan drug designations from the U.S. Food and Drug Administration ("FDA") as well as Advanced Therapeutic Medicinal Product ("ATMP") classification from the European Medicines Agency ("EMA"). In October 2016, we received a satisfactory safety evaluation by our independent Data Safety Monitoring Board based on safety data then available from the first 19 patients enrolled in the trial. A subsequent interim analysis was conducted after approximately 50% of patients reached the six-month follow-up milestone, the results of which were publicly released on March 8, 2018 that the therapy continued to be well tolerated and was deemed non-futile for therapeutic effect. On January 18, 2018, we announced completion of enrollment (110 patients) of the TRex Study. Ischemic Repair (CD34 Cell Technology) Our CD34 cell technology has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted. Through the administration of CD34 cells, we seek to promote the development and formation of new blood vessels and thereby increase blood flow to the impacted area. We believe that conditions caused by underlying ischemic injury can be improved through our CD34 cell technology, including critical limb ischemia ("CLI"), coronary microvascular disfunction ("CMD") and refractory angina ("RfA"). Published reports in Circulation Cardiovascular Interventions, Atherosclerosis, Stem Cells and Circulation Journal, provide preliminary evidence that CD34 cell therapy is safe and can exert significant therapeutic effects in patients with CLI, a condition in which blood flow to the legs is severely impaired, causing pain and non-healing ulcers and, ultimately, potentially resulting in the need for amputation. Our Clinical Trial Notification for a pivotal Phase 2 trial investigating our product candidate in CLI CLBS12 was submitted to the Japanese Pharmaceutical and Medical Device Agency ("PMDA") and was cleared to proceed. The protocol design was agreed to with PMDA, the study was opened for enrollment in December 2017 and treatment or the first patient was announced in March 2018. Based on our discussions with the PMDA, we expect that a successful outcome of this trial will qualify CLBS12 for consideration of early conditional approval in Japan. In anticipation of a successful trial outcome and the possibility of conditional approval, we continue to seek a local partner for CLBS12 in Japan. Furthermore, we submitted grant applications in an effort to seek non-dilutive financing to investigate the CD34 technology for additional clinical indications in the United States and on October 2, 2017 we announced the award of a $1.9 million grant from the National Institutes of Health to support a clinical study of CD34 cells in patients with coronary microvascular dysfunction and we are targeting the initiation of the study by the second quarter of 2018. Additional Out-licensing Opportunities Our broad intellectual property portfolio of cell therapy assets includes notable programs available for out-licensing in order to continue their clinical development. These include additional indications for our Treg product and additional indications for our CD34 cell technology. Our current long-term strategy focuses on advancing our therapies through development with the aim of eventually obtaining market authorization, either alone or with partners, to provide treatment options to patients suffering from life-threatening medical conditions. We believe that we are positioned to realize potentially meaningful value increases within our own proprietary pipeline if we are successful advancing our product candidates to their next significant development milestones. Discontinued Operations On May 18, 2017, we completed the previously announced sale of our remaining 80.1% membership interest in PCT, LLC, a Caladrius company ("PCT") to Hitachi Chemical Co. America, Ltd. ("Hitachi"), pursuant to the Interest Purchase Agreement (the "Purchase Agreement") dated as of March 16, 2017, by and among us, PCT and Hitachi (the "2017 Hitachi Transaction"), for $75.0 million in cash plus an additional cash adjustment of $4.4 million based on PCT’s cash and outstanding indebtedness as of the closing date and a potential future milestone payment (see Note 3). The sale of PCT represented a strategic shift that has had a major effect on our operations, and therefore, all periods presented were adjusted to reflect PCT as discontinued operations. PCT is now known as Hitachi Chemical Advanced Therapeutic Systems (HCATS). Basis of Presentation The accompanying Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of December 31, 2017 and 2016, and the results of its operations and its cash flows for the years then ended. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values and income taxes. Accordingly, actual results could differ from those estimates and assumptions. An accounting policy is considered to be critical if it is important to the Company’s financial condition and results of operations and if it requires management’s most difficult, subjective and complex judgments in its application. Principles of Consolidation The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly-owned and partially-owned subsidiaries and affiliates, as well as the operations of our former subsidiaries PCT, LLC, a Caladrius company, NeoStem Family Storage, LLC, and PCT Allendale, LLC entities (collectively the "PCT Segment") through May 18, 2017, representing the date which these entities were sold to Hitachi (see Note 3). The PCT Segment is reported in discontinued operations. All intercompany activities have been eliminated in consolidation, except for intercompany activities between Caladrius and the PCT Segment, which are reported without intercompany eliminations in continuing operations and discontinued operations, respectively.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Cash and Cash Equivalents

Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.

Concentration of Risks

We are subject to credit risk from our portfolio of cash, cash equivalents, restricted cash, and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States. Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.

Marketable Securities

The Company determines the appropriate classification of our marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of our marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. We regularly review all of our investments for other-than-temporary declines in fair value. Our review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost basis. When we determine that the decline in fair value of an investment is below our accounting basis and this decline is other-than-temporary, we reduce the carrying value of the security we hold and record a loss for the amount of such decline.

Property, Plant, and Equipment

The cost of property, plant and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property, plant and equipment are as follows:



Furniture and fixtures	10 years
Computer equipment	3 years
Software	3 years
Leasehold improvements	Life of lease

Long-lived Assets

Long-lived assets consist of property, plant and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.

Share-Based Compensation

The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.

Income (Loss) Per Share

Basic income (loss) per share is based on the weighted effect of all common shares issued and outstanding, and is calculated by dividing net income (loss) attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share, which is calculated by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares used in the basic income (loss) per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted income (loss) per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred from continuing operations in all periods presented.

Income Taxes

The Company recognizes (a) the amount of taxes payable or refundable for the current year and (b) deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company’s financial statements or tax returns.

The Tax Cuts and Jobs Act (“the Act”) was enacted on December 22, 2017. The income tax effects of changes in tax laws are recognized in the period when enacted. The Act provides for significant tax law changes and modifications with varying effective dates, which include reducing the U.S. federal corporate income tax rate from 35% to 21%, creating a territorial tax system (with a one-time mandatory repatriation tax on previously deferred foreign earnings), and allowing for immediate capital expensing of certain qualified property acquired and placed in service after September 27, 2017 and before January 1, 2023.

The Company continues to evaluate the accounting for uncertainty in tax positions at the end of each reporting period. The guidance requires companies to recognize in their financial statements the impact of a tax position if the position is more likely than not of being sustained if the position were to be challenged by a taxing authority. The position ascertained inherently requires judgment and estimates by management. The Company recognizes interest and penalties as a component of income tax expense.

Treasury Stock

Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.

Research and Development Costs

Research and development (“R&D”) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.

To further drive the Company’s cell therapy initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company’s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.

New Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This ASU requires that a lessee recognize lease assets and lease liabilities for those leases classified as operating leases. The guidance is effective for interim and annual periods beginning after December 15, 2018, and will be applied at the beginning of the earliest period presented using a modified retrospective approach. This ASU may have a material impact on the Company’s financial statements. The impact on the Company’s results of operations is currently being evaluated. The impact of the ASU is non-cash in nature and will not affect the Company’s cash position.

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting. This ASU simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, accounting for forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance was effective for interim and annual periods beginning after December 15, 2016. The adoption of this new guidance did not have a material effect on the consolidated results of operations, cash flows, and financial position.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 clarifies how companies present and classify certain cash receipts and cash payments in the statement of cash flows where diversity in practice exists. ASU 2016-15 is effective in first quarter of fiscal 2018 and earlier adoption is permitted. The Company is currently evaluating the effect that the updated standard will have on the consolidated financial statements and related disclosures.

In October 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory. ASU 2016-16 requires the income tax consequences of intra-entity transfers of assets other than inventory to be recognized as current period income tax expense or benefit at the transaction date and removes the option to defer and amortize the consolidated tax consequences of intra-entity transfers. The new standard will be effective on January 1, 2018 and will be adopted using a modified retrospective approach which requires a cumulative effect adjustment to retained earnings as of the beginning of the period of adoption. Early adoption is permitted at the beginning of a fiscal year. The Company is currently evaluating the effect that the updated standard will have on the consolidated financial statements and related disclosures.

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The new standard will be effective on January 1, 2018 and the Company early adopted the standard in 2017, with all adjustments reflected as of the beginning of the fiscal years reported.

In May 2017, the FASB issued ASU 2017-09, "Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting," to provide clarity and reduce both diversity in practice and cost complexity when applying the guidance in Topic 718 to a change to the terms and conditions of a stock-based payment award. ASU 2017-09 also provides guidance about the types of changes to the terms or conditions of a share-based payment award that require an entity to apply modification accounting in accordance with Topic 718. For all entities, including emerging growth companies, the standard is effective for annual periods beginning after December 15, 2017, and for interim periods therein. Early adoption is permitted. The Company does not expect the adoption of this ASU to have a material impact on its consolidated financial statements.

Collaboration and Hitachi License Agreement

12 Months Ended

Dec. 31, 2017

Business Combinations [Abstract]

Collaboration and Hitachi License Agreement

2016 Hitachi Transaction

On March 11, 2016, PCT entered into a global collaboration with Hitachi (the "2016 Hitachi Transaction"). This collaboration consists of an equity investment in and a license agreement with PCT.

Under the equity investment agreement, Hitachi purchased a 19.9% membership interest in PCT for $19.4 million of which $15.0 million of proceeds was distributed to Caladrius from PCT and $4.4 million remained at PCT to be used for the continued expansion and improvements at PCT in support of commercial product launch readiness as well as for general corporate purposes.

PCT and Hitachi also entered into an exclusive license agreement for the acceleration of the creation of a global commercial cell therapy development and manufacturing expertise in Asia pursuant to which PCT received $5.6 million from Hitachi in 2016. PCT licensed certain cell therapy technology and know-how (including an exclusive license in Asia) and agreed to provide Hitachi with certain training and support. As additional consideration, Hitachi agreed to pay PCT royalties on contract revenue generated in Asia for a minimum of ten years. In connection with the 2017 Hitachi Transaction below, this exclusive license agreement was terminated.

2017 Hitachi Transaction

On May 18, 2017, the Company sold its remaining 80.1% membership interest in PCT to Hitachi pursuant to the Purchase Agreement, dated March 16, 2017, by and among Caladrius PCT and Hitachi (the "2017 Hitachi Transaction"). The aggregate purchase price to the Company consisted of (i) $75.0 million in cash, (ii) $4.4 million, representing additional consideration based on PCT’s cash and outstanding indebtedness as of the closing date, and (iii) a potential future milestone payment of $5.0 million if PCT achieves $125 million in cumulative revenue (excluding clinical service reimbursables) (the “Milestone”) for the period from January 1, 2017 through December 31, 2018 (the “Milestone Period”).

Hitachi paid the Company $5.0 million in March 2017 as an advance payment pending shareholder approval of the transaction and other closing conditions. On the closing date, the Company received $65.0 million, with an additional $5.0 million of the purchase consideration (the "Escrow Amount") deposited into an escrow account to cover potential indemnification claims against Caladrius. The Escrow Amount is classified as restricted cash on the balance sheet as of December 31, 2017. In June 2018, the escrow agent will disburse to the Company the Escrow Amount less (i) that portion of the Escrow Amount previously paid in satisfaction of claims for indemnification pursuant to the terms of the Purchase Agreement and (ii) that portion of the Escrow Amount that is determined, in the reasonable judgment of Hitachi, to be necessary to satisfy all unsatisfied or disputed claims for indemnification specified in any claim notice delivered to the Company. The Company also received the $4.4 million additional consideration payment in July 2017. The Company incurred approximately $6.9 million in transaction costs related to the 2017 Hitachi Transaction, including $4.3 million in retention payments to PCT employees, of which 50% was paid in June 2017, and the other 50% payable on the one year anniversary of the closing date.

Concurrent with the signing of the Purchase Agreement, on March 16, 2017, Caladrius entered into a Retention and Incentive Agreement with Robert A. Preti, a former Caladrius director and a co-founder and the President of PCT, (the “Retention Agreement”). The Retention Agreement superseded all prior agreements and understandings between Dr. Preti and Caladrius regarding the subject matter of the Retention Agreement. Among other things, the Retention Agreement provided for:


•	Simultaneously with the closing of the 2017 Hitachi Transaction, Caladrius paid to Dr. Preti $1.9 million (the “First Retention Payment”).

•

As an incentive to remain employed with PCT and to use commercially reasonable efforts to cause PCT to maximize its overall performance and in particular to achieve the Milestone (but not contingent upon achieving the Milestone), Dr. Preti will receive a lump-sum cash retention and incentive payment equal to $1.9 million for the period from the closing date until the date one year after the date of the closing date (the “Anniversary Date”), subject to Dr. Preti’s continued employment with PCT through the Anniversary Date (the “Second Retention Payment”).


•	Dr. Preti will be entitled to 5% of the Milestone payment if it is successfully earned.

Available-for-Sale-Securities

12 Months Ended

Dec. 31, 2017

Available-for-sale Securities [Abstract]

Available-for-Sale-Securities

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents in our Consolidated Balance Sheets (in thousands):



	December 31, 2017									December 31, 2016
	Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value		Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Corporate debt securities	$	42,701.0	$	—	$	(28.0	)	$	42,673.0	$	—	$	—	$	—	$	—
Money market funds	9,211.5		—		—			9,211.5		4,426.8		—		—		4,426.8
Total	$	51,912.5	$	—	$	(28.0	)	$	51,884.5	$	4,426.8	$	—	$	—	$	4,426.8

Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on our Consolidated Balance Sheets (in thousands):



	December 31, 2017		December 31, 2016
Cash and cash equivalents	$	25,967.8	$	4,426.8
Marketable securities	25,916.7		—
Total	$	51,884.5	$	4,426.8

The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):



	December 31, 2017
	Amortized Cost		Estimated Fair Value
Less than one year	$	51,912.5	$	51,884.5
Greater than one year	—		—
Total	$	51,912.5	$	51,884.5

Property, Plant and Equipment

12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Property, plant, and equipment consisted of the following (in thousands):



	December 31,
	2017			2016
Lab equipment	$	—		$	181.6
Furniture and fixtures	25.4			288.2
Computer equipment	998.3			1,173.4
Software	—			99.5
Leasehold improvements	65.6			115.7
Property, plant and equipment, gross	1,089.3			1,858.4
Accumulated depreciation	(832.4		)	(1,153.0		)
Property, plant and equipment, net	$	256.9		$	705.4

The Company’s results included depreciation expense of approximately $0.4 million and $0.5 million for the years ended December 31, 2017 and 2016, respectively.

Loss Per Share

12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Loss Per Share

For the years ended December 31, 2017 and 2016 the Company incurred net losses from continuing operations and therefore no common stock equivalents were utilized in the calculation of loss per share as they are anti-dilutive in the periods presented. At December 31, 2017 and 2016 the Company excluded the following potentially dilutive securities:



	December 31,
	2017	2016
Stock Options	1,072,499	953,690
Warrants	209,818	388,062
Restricted Shares	181,908	126,849
Restricted Stock Units	10,260	—

Fair Value Measurements

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value Measurements

Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:

Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.

Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.

The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2017 and December 31, 2016 were as follows (in thousands):



	December 31, 2017								December 31, 2016
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Marketable securities - available for sale	$	—	$	25,916.7	$	—	$	25,916.7	$	—	$	—	$	—	$	—
	$	—	$	25,916.7	$	—	$	25,916.7	$	—	$	—	$	—	$	—

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Accrued Liabilities

12 Months Ended

Dec. 31, 2017

Accrued Liabilities [Abstract]

Accrued Liabilities

Accrued liabilities were as follow (in thousands):



	December 31,
	2017		2016
Salaries, employee benefits and related taxes	$	1,389.2	$	1,406.3
Retention payments	2,233.0		—
Professional fees	286.7		224.5
CIRM upfront funding - current	2,445.9		—
Other	1,456.1		1,028.6
	$	7,810.9	$	2,659.4

Debt	12 Months Ended
Debt	Dec. 31, 2017
Debt Disclosure [Abstract]
Debt	Debt Notes Payable As of December 31, 2017 and December 31, 2016, the Company had notes payable of approximately $0.2 million and $0.7 million, respectively. The notes relate to certain insurance policies and equipment financings, require monthly payments, and mature within one year. Long-Term Debt On September 26, 2014, the Company entered into a loan and security agreement (the “Loan and Security Agreement”) with Oxford Finance LLC (together with its successors and assigns, the “Lender”) pursuant to which the Lender disbursed $15.0 million (the “Loan”). The debt offering/issuance costs have been recorded as debt issuance costs in other assets in the consolidated balance sheet, and were amortized to interest expense throughout the life of the Loan using the effective interest rate method. In March 2016, concurrent with the 2016 Hitachi Transaction (see Note 3), the Company and the Lender entered into an amendment to the Loan and Security Agreement whereby (i) the Company paid $7.0 million to Lender, comprising principal, interest and early termination fees, (ii) the Company's subsidiaries PCT, PCT Allendale, LLC, and NeoStem Family Storage, LLC (collectively the "Removed Borrowers") were removed as borrowers under the Loan, (iii) Lender's security interests in any and all assets of the Removed Borrowers were released, (iv) the interest only period on the remaining outstanding Loan balance was extended until January 1, 2017, and (v) in the event the Company received gross proceeds from the sale or issuance of any equity securities or subordinated debt, or any partnership, licenses, collaboration, dividend, grant or asset sale through March 31, 2017, 20% of such proceeds will be paid to Lender, up to a $3.0 million maximum as additional partial repayment of Loan. On September 14, 2016, concurrent with the Company's September 2016 Registered Direct Offering and Concurrent Private Placement (see Note 11), the Company repaid $3.0 million of such proceeds to the Lender. The outstanding balance was approximately $5.7 million at December 31, 2016. In May 2017, concurrent with the 2017 Hitachi Transaction (see Note 3), the Company retired the Loan in full, and paid $4.9 million to Lender, comprising principal, interest and early termination fees. The Company was making interest-only payments on the outstanding amount of the Loan on a monthly basis at a rate of 8.50% per annum. During the years ended December 31, 2017 and 2016, the Company recognized $0.4 million and $1.7 million of interest expense, respectively, related to the Loan and Security Agreement.

Redeemable Securities - Non-Controlling Interests	12 Months Ended
Redeemable Securities - Non-Controlling Interests	Dec. 31, 2017
Investments, Debt and Equity Securities [Abstract]
Redeemable Securities - Non-Controlling Interests	Redeemable Securities - Non-Controlling Interests Under the 2016 Hitachi Transaction (see Note 3), Hitachi, at any time following the tenth anniversary of the 2016 Hitachi Transaction closing date on March 11, 2016, had the right on one occasion to require Caladrius or PCT to purchase all or some of the equity securities in PCT then held by Hitachi ("Hitachi Put Right") for an amount equal to the lower of (i) the fair market value of the Hitachi equity holdings and (ii) the original purchase price paid of $19.4 million on March 11, 2016 for its 19.9% ownership interest, plus interest at a rate of 2.0% per annum compounded annually; provided, however, that if Hitachi's ownership interests increased subsequent to its initial ownership interest, and it offered to sell its equity holdings in excess of 21% of PCT’s outstanding equity securities, then the Company would have been required to purchase all such equity holdings of Hitachi Chemical but in no event would the aggregate purchase price of such Hitachi Chemical equity holdings exceed $20.5 million plus interest at the rate of 2.0% per annum compounded annually. As of December 31, 2016, since Hitachi had the right to deliver the equity interests in PCT it held in exchange for cash from Caladrius or PCT, the initial $19.4 million value of the non-controlling interest was considered redeemable equity, requiring it to be treated as mezzanine equity. Redeemable non-controlling interest is required to be initially measured at the initial carrying amount. If the non-controlling interest is not currently redeemable and also not probable of becoming redeemable (e.g., it is not probable a contingency that triggers redemption will be met), the non-controlling interest should be classified in mezzanine equity. Concurrent with 2017 Hitachi Transaction (see Note 3), the Hitachi Put Right was eliminated, and $14.7 million previously classified as Redeemable Securities was classified to Additional Paid in Capital. In addition, the remaining portion classified as Redeemable Securities of $4.7 million was classified to Non-Controlling Interests, representing Hitachi's ownership interest in PCT at the time of the 2016 Hitachi Transaction, which was subsequently eliminated upon the 2017 Hitachi transaction and included the PCT gain on sale.

Stockholders' Equity

12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Stockholders' Equity

Reverse Stock Split

On July 28, 2016, the Company implemented the Reverse Stock Split, as authorized at the annual meeting of stockholders on June 22, 2016 and unanimously approved by the Company’s board of directors on July 22, 2016. The Reverse Stock Split became effective on July 27, 2016 at 5:00pm and the common stock of the Company began trading on The Nasdaq Capital Market on a post-split basis at the open of business on July 28, 2016. As of July 28, 2016, every ten shares of the Company’s issued and outstanding common stock were combined into one share of its common stock, except to the extent that the Reverse Stock Split resulted in any of the Company’s stockholders owning a fractional share, which was rounded up to the next highest whole share. In connection with the Reverse Stock Split, there was no change in the nominal par value per share of $0.001.

All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from “common stock” to “Additional paid-in capital” in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.

Equity Plans

The Company's 2015 Equity Compensation Plan (the "2015 Equity Plan") was adopted by the stockholders of the Company on July 14, 2015, with 440,000 shares initially reserved for future awards under the 2015 Equity Plan (as adjusted in the manner described below, the “Share Reserve”). These shares will be available for issuance pursuant to non-qualified stock options, incentive stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted shares, deferred share units, or other kinds of equity based compensation awards. Concurrent with the adoption of the 2015 Equity Plan, no future awards will occur under the 2009 Amended and Restated Equity Compensation Plan (the “2009 Plan”). The 2015 Equity Plan’s initial reserve of shares will automatically increase for 10 years, on each January 1^st beginning with 2016, by a number of shares equal to the lesser of (i) four percent (4%) of the total number of our shares outstanding on December 31^st of the preceding calendar year, (ii) such lesser number as the 2015 Plan’s administrator may earlier designate in writing, and (iii) 17,600 shares, which equals four percent (4%) of the initial reserve of 440,000 shares. In addition, the Share Reserve will include shares that are currently subject to awards under our 2009 Equity Plan but that are not issued due to their forfeiture, cancellation, or other settlement.

The 2009 Equity Plan was originally adopted by the stockholders of the Company on May 8, 2009. On October 29, 2009, the stockholders of the Company approved an amendment to the 2009 Equity Plan to increase the number of shares of common stock available for issuance thereunder from 38,000 to 97,500. At the 2010 Annual Meeting of Stockholders of the Company held on June 2, 2010, the stockholders approved an amendment to increase this number to 137,500. At a Special Meeting of Stockholders of the Company held on January 18, 2011, the stockholders approved an amendment to increase this number to 177,500. At the 2011 Annual Meeting of Stockholders of the Company held on October 14, 2011, the stockholders approved an amendment to increase this number to 237,500. At the 2012 Annual Meeting of Stockholders of the Company held on October 5, 2012, the stockholders approved an amendment to (i) merge the 57,000 shares reserved for issuance under the Company's 2009 Non-U.S. Based Equity Compensation Plan (the "Non-U.S. Plan") with and into the 2009 Equity Plan, and (ii) increase by 45,000 the aggregate number of shares authorized for issuance under the 2009 Equity Plan (the “2009 Amended & Restated Equity Plan”). At the Company's 2013 Annual Meeting held October 3, 2013, the Company's stockholders approved an amendment to the 2009 Amended & Restated Equity Plan to increase the number of shares authorized for issuance to 599,500. At the Company's 2014 Annual Meeting held October 6, 2014, the Company's stockholders approved an amendment to the 2009 Amended & Restated Equity Plan to increase the number of shares authorized for issuance to 899,500.

The Company's 2003 Equity Participation Plan (the “2003 Equity Plan”) expired in 2013 and accordingly, equity awards under the 2003 Equity Plan can no longer be issued. The Company's 2009 Equity Compensation Plan (the “2009 Equity Plan”) makes up to 899,500 shares of common stock of the Company (as of December 31, 2017) available for issuance to employees, consultants, advisors and directors of the Company and its subsidiaries pursuant to incentive or non-statutory stock options, restricted and unrestricted stock awards and stock appreciation rights.

All stock options under the 2003 Equity Plan and 2009 Equity Plan were granted and the 2015 Equity Plan are granted at the fair market value of the common stock at the grant date. Stock options vest either on the date of grant, ratably over a period determined at time of grant, or upon the accomplishment of specified business milestones, and generally expire 2, 3, or 10 years from the grant date depending on the status of the recipient as a consultant, employee or director of the Company.

The number of remaining shares authorized to be issued under the various equity plans are as follows as of December 31, 2017:



	2003 Equity Plan		2009 Equity Plan		2015 Equity Plan
Shares Authorized for Issuance	25,000		899,500		440,000
2016 Evergreen increase of shares	—		—		226,932
2017 Evergreen increase of shares					328,232
Outstanding Stock Options	(5,006	)	(432,916	)	(634,577	)
Exercised Stock Options	(925	)	(8,093	)	(3,835	)
Restricted stock or equity grants issued under Equity Plans	(8,922	)	(156,467	)	—
Shares Expired	(10,147	)	(302,024	)	(314,254	)
Total common shares remaining to be issued under the Equity Plans	—		—		42,498

The Company adopted an employee stock purchase plan effective January 1, 2013, and authorized 50,000 shares under the plan (the "2012 ESPP"). The plan has two six-month offering periods per year under which eligible employees may contribute up to 15% of their compensation toward the purchase of the Company's common stock per offering period (with a $25,000 cap per calendar year). The employee's purchase price is equal to (i) 85% of the closing price of a share of the Company's common stock on the enrollment date of such offering period or (ii) 85% of the closing price of a share of the Company's common stock on the Exercise Date of such Offering Period, whichever is lower. On May 16, 2017, the Company's stockholders approved an amendment and restatement to the 2012 ESPP (the "2017 ESPP") in order to effect an increase of authorized shares from 50,000 to 100,000. During the year ended December 31, 2017, 21,924 shares were issued under the 2017 ESPP. At December 31, 2017, the Company had 32,530 shares of the Company's common stock available for future grant in connection with this plan.

Equity Issuances

March 2016 Private Placement

On March 10, 2016, the Company entered into a securities purchase agreement with certain investors, pursuant to which the Company issued and sold in a private placement an aggregate of 141,844 shares of common stock and two-year warrants to purchase up to an aggregate of 141,844 shares of the Company's common stock, at an exercise price of $10.00 per share. The unit purchase price for a share of the Company's common stock and warrant to purchase one share of the Company's common stock was $7.05 per unit, with $1.0 million of gross proceeds received by the Company. On April 8, 2016, the Company filed a registration statement on Form S-3 to register the shares of common stock and the shares of common stock issuable upon exercise of the warrants acquired in the private placement, which registration statement became effective on June 7, 2016.

September 2016 Registered Direct Offering and Concurrent Private Placement

On September 14, 2016, the Company entered into a securities purchase agreement (the “RD Purchase Agreement”) with a single institutional investor (the “Purchaser”), pursuant to which the Company issued and sold to the Purchaser, in a registered direct offering, an aggregate of 847,458 shares of the Company’s common stock at a purchase price of $4.72 per share. The gross proceeds to the Company from the registered direct offering of the shares of common stock were $4.0 million.

In concurrent private placements, on September 14, 2016, the Company entered into Securities Purchase Agreements (each a “Private Placement Purchase Agreement” and, collectively, the “Private Placement Purchase Agreements”) with certain accredited investors (the “Investors”) with whom it had a substantive, pre-existing relationship, including certain existing stockholders, for the sale by the Company of an aggregate of 4,449,153 shares of common stock, at a purchase price of $4.72 per share. The investments will be placed in two tranches: (i) $12.6 million upon an initial closing (the “Initial Closing”), and (ii) $8.4 million, subject to certain conditions, including the enrollment of 70 subjects in the Company’s Phase 2 CLBS03 clinical trial, in a second closing (the “Second Closing”). As of March 31, 2017, $6.0 million of the Initial Closing tranche had not been received from a single investor, who was in breach of his obligations under the Private Placement Purchase Agreement. This investor had also committed to fund $4.0 million in the Second Closing. As a result, the Company terminated the Private Placement Purchase Agreement with this investor in the first quarter of 2017. In 2017, the Company met the conditions of the Second Closing, and received the remaining $4.4 million in proceeds in accordance with the terms of the Second Closing tranche and issued 932,204 shares of common stock.

Aspire Purchase Agreement

In November 2015, the Company entered into a common stock purchase agreement (the "Purchase Agreement") with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”), which provided that, subject to certain terms and conditions and Nasdaq rules, Aspire Capital was committed to purchase up to an aggregate of $30 million of shares (limited to a maximum of approximately 1.1 million shares, unless stockholder approval was obtained or certain minimum sale price levels were reached) of the Company's common stock over a 24-month term. The Company issued 319,776 shares of common stock under the Purchase Agreement with Aspire for gross proceeds of $1.5 million, which Purchase Agreement expired in November 2017.

Stock Options and Warrants

The following table summarizes the activity for stock options and warrants for the year ended December 31, 2017:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2016	952,790		$	39.90	7.60	$	—	388,062		$	76.50	1.24	$	—

Changes during the Year:
Granted	448,057		$	11.70				—		$	—
Exercised	(3,835	)	$	4.70				—		$	—
Forfeited	(244,413	)	$	18.80				(1,937	)	$	700.00
Expired	(80,100	)	$	35.80				(176,307	)	$	103.90
Outstanding at December 31, 2017	1,072,499		$	33.50	4.76	$	0.1	209,818		$	53.20	0.95	$	—
Vested at December 31, 2017 or expected to vest in the future	1,072,107		$	33.5	4.76	$	0.1	209,818		$	53.20	0.95	$	—
Exercisable at December 31, 2017	1,063,759		$	32.9	4.77	$	0.1	209,818		$	53.20	0.95	$	—

Restricted Stock

During the years ended December 31, 2017 and 2016, the Company issued restricted stock for services as follows ($ in thousands, except share data):




	2017		2016
Number of Restricted Stock Issued	181,908		126,849
Value of Restricted Stock Issued	$	627.7	$	698.1

The weighted average estimated fair value of restricted stock issued for services in the years ended December 31, 2017 and 2016 was $3.45 and $5.50 per share, respectively. The fair value of the restricted stock was determined using the Company’s closing stock price on the date of issuance. The vesting terms of restricted stock issuances are generally between one to four years.

Share-Based Compensation

12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-Based Compensation

Share-based Compensation

We utilize share-based compensation in the form of stock options and restricted stock. The following table summarizes the components of share-based compensation expense for the years ended December 31, 2017 and 2016 ($ in thousands):



	Year Ended December 31,
	2017		2016
Research and development	$	268.9	$	262.3
General and administrative	1,694.3		1,511.5
Discontinued operations	888.9		830.6
Total share-based compensation expense	$	2,852.1	$	2,604.3

The approval of the 2017 Hitachi Transaction (see Note 3) by our stockholders resulted in a change in control under our equity compensation plans (as defined in the 2009 Plan and the 2015 Equity Plan, and, together with the 2009 Plan, the “Equity Compensation Plans”). Accordingly, all outstanding unvested equity awards were accelerated upon the Closing Date, resulting in an acceleration of $1.9 million of equity compensation for the years ended December 31, 2017. In addition, in connection with the 2017 Hitachi Transaction, the Company agreed to extend the post-termination option exercise period for all PCT employees transitioning to Hitachi from 90 days to the earlier of (i) two years (May 18, 2019) or (ii) the date of the employees' termination from PCT. The post-termination option exercise period modification resulted in an additional expense of $0.3 million which was recorded entirely during the three months ended June 30, 2017 and recorded in discontinued operations, since there were no future service requirements to receive the extended benefit.

Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at December 31, 2017 were as follows ($ in thousands):



	Stock Options		Restricted Stock
Unrecognized compensation cost	$	39.5	$	97.2
Expected weighted-average period in years of compensation cost to be recognized	0.61		1.84

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the years ended December 31, 2017 and 2016 were as follows ($ in thousands):



	Stock Options
	Year Ended December 31,
	2017		2016
Total fair value of shares vested	$	5,001.7	$	2,359.8
Weighted average estimated fair value of shares granted	1.72		3.23

Valuation Assumptions

The fair value of stock options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company’s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees.

The range of assumptions made in calculating the fair values of stock options was as follow:



	Stock Options
	Year Ended December 31,
	2017	2016
Expected term - minimum (in years)	6	5
Expected term - maximum (in years)	6	10
Expected volatility - minimum	71%	73%
Expected volatility - maximum	74%	76%
Weighted Average volatility	35%	74%
Expected dividend yield	—	—
Risk-free interest rate - minimum	1.99%	1.07%
Risk-free interest rate - maximum	2.28%	2.19%

Research Funding	12 Months Ended
Research Funding	Dec. 31, 2017
Research and Development [Abstract]
Research Funding	Research Funding California Institute of Regenerative Medicine Grant Award In February 2017, the California Institute for Regenerative Medicine ("CIRM") awarded us funds of up to $12.2 million to support the T-Rex Study. The funding will be based upon the achievement of certain milestones related to the proportion of subjects enrolled in California, as well as manufacturing and development costs incurred in California. We received $5.7 million in initial funding in May 2017, and a $1.9 million milestone payment in December 2017, of which the total will be amortized over the estimated award period through July 2020 as a reduction to the related research and development expenses. As of December 31, 2017, $2.4 million of the funding received is recorded in accrued liabilities, representing the amount expected to be recognized over the next 12 months, and $3.9 million of the funding received is recorded in other long-term liabilities. During the year ended December 31, 2017, the Company amortized and recognized a $1.3 million credit to research and development related to CIRM funds received.

Income Taxes

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Income Taxes

The Tax Cuts and Jobs Act (“the Act”) was enacted on December 22, 2017. The income tax effects of changes in tax laws are recognized in the period when enacted. The Act provides for significant tax law changes and modifications with varying effective dates, which include reducing the U.S. federal corporate income tax rate from 35% to21%, creating a territorial tax system (with a one-time mandatory repatriation tax on previously deferred foreign earnings), and allowing for immediate capital expensing of certain qualified property acquired and placed in service after September 27, 2017 and before January 1, 2023.

In response to the enactment of the Act in late 2017, the U.S. Securities and Exchange Commission issued Staff Accounting Bulletin No. 118 (“SAB 118”) to address situations where the accounting is incomplete for certain income tax effects of the Tax Act upon issuance of an entity’s financial statements for the reporting period in which the Tax Act was enacted. Under SAB 118, a company may record provisional amounts during a measurement period for specific income tax effects of the Tax Act for which the accounting is incomplete but a reasonable estimate can be determined, and when unable to determine a reasonable estimate for any income tax effects, report provisional amounts in the first reporting period in which a reasonable estimate can be determined. While the Company was able to make reasonable estimates of the impact of the tax effects of the Tax Act, the final impact of the Tax Act may differ from those estimates, including, but not limited to changes in our interpretations and assumptions, additional guidance that may be issued by the IRS, return to provision differences and state rate adjustments. As guidance and technical corrections are issued in the upcoming quarters, the Company will record updates to its original provisional estimates.

The Company remeasured certain U.S. deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. The provisional amount recorded related to the remeasurement of the deferred tax balance was tax expense of $30 million which was offset by a reduction in the valuation allowance resulting in no tax expense.

The provision (benefit) for income taxes is based on loss from operations before provision for income taxes and noncontrolling interests as follows ($ in thousands):



	Years Ended December 31,
	2017			2016
United States	$	(27,698	)	$	(31,258	)
	$	(27,698	)	$	(31,258	)

The provision (benefit) for income taxes was as follows ($ in thousands):



		Years Ended December 31,
		2017			2016
Current
	U.S. Federal	$	(9,310	)	$	—
	State and local	(1,641		)	—
		$	(10,951	)	$	—
Deferred
	U.S. Federal	$	(576	)	$	—
	State and local	—			—
		$	(576	)	$	—
Total
	U.S. Federal	$	(9,886	)	$	—
	State and local	(1,641		)	—
		$	(11,527	)	$	—

The provision (benefit) for income taxes is determined by applying the U.S. Federal statutory rate of 34% to income before income taxes as a result of the following ($ in thousands):



	Years Ended December 31,
	2017			2016
U.S. Federal benefit at statutory rate	$	(9,417	)	$	(10,628	)
State and local (benefit) / expense net of U.S. federal tax	(1,641		)	2,759
Permanent non deductible expenses for U.S. taxes	107			80
AMT credit benefit	(576		)	—
True-up of prior year net operating loss	—			(2,371		)
Effect of change in deferred tax rate	29,809			(44		)
Valuation allowance for deferred tax assets	(29,809		)	10,204
Tax provision benefit	$	(11,527	)	$	—

Deferred income taxes at December 31, 2017 and 2016 consist of the following ($ in thousands):



	December 31,
	2017			2016
Deferred Tax Assets:
Accumulated net operating losses (tax effected)	$	60,171		$	79,131
CIRM funding	1,780			—
Deferred rent	3			314
Share-based compensation	2,656			11,562
Intangibles	270			429
Charitable contributions	11			424
Partnership interest	—			3,858
Capital loss carry-forward	—			6,988
Accumulated depreciation	22			—
Accrued payroll	682			—
AMT credit	575			—
Other	526			659
Deferred tax assets	66,696			103,365

Deferred Tax Liabilities:
Accumulated depreciation	$	—		$	(119	)
Deferred tax liabilities	—			(119		)
	66,696			103,246
Valuation allowance	(66,121		)	(103,246		)
Net deferred tax asset	$	575		$	—

In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets. Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.

As of December 31, 2017 and 2016, the Company had approximately $210.3 million and $232.7 million, respectively of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s NOLs could be limited in the event of a change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible.

The Company performed an analysis and determined that they have had ownership change of greater than 50% over a 3 year testing period. The last ownership change was determined to be in 2015. Based on a market capitalization of $124.5M and using an applicable federal rate of 2.5% the annual limitation would be approximately $3.0 million. Post change losses from June 3, 2015 through December 31, 2016 would not be subject to 382 limitations. Additionally the Company would be able to further increase NOL limitations by the realized built in gain on the sale of PCT in May of 2017.

The Company applies the FASB’s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense.

As of December 31, 2017, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.

The Company completed the audit of its federal tax returns for the years 2012 and 2013 during the fourth quarter of 2016. The audit resulted in an adjustment to the Company’s NOL carryforward. For years prior to 2014 the federal statute of limitations is closed for assessing tax. The Company’s state tax returns remain open to examination for a period of three to four years from date of filing. The Company ceased doing business in China in 2012. After 2012, the Company had no foreign tax filing obligations. The foreign returns filed for 2012 and prior are subject to examination for five years.

Discontinued Operations

12 Months Ended

Dec. 31, 2017

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

PCT Segment

On May 18, 2017, the Company sold its remaining 80.1% membership interest in PCT to Hitachi pursuant to the 2017 Hitachi Transaction (see Note 3). The aggregate purchase price to the Company consisted of (i) $75.0 million in cash, (ii) $4.4 million, representing additional consideration based on PCT’s cash and outstanding indebtedness as of the closing date, and (iii) a potential future milestone payment of $5.0 million if PCT achieves $125 million in cumulative revenue (excluding clinical service reimbursables) for the period from January 1, 2017 through December 31, 2018. The Company has determined that the fair value of the milestone payment as of the closing date was valued at zero.

Hitachi paid the Company $5.0 million in March 2017 as an advance payment pending shareholder approval of the transaction and other closing conditions. On the Closing Date, the Company received $65.0 million, with an additional $5.0 million of the purchase consideration (the "Escrow Amount") deposited into an escrow account to cover potential indemnification claims against Caladrius. The Escrow Amount is classified as restricted cash on the balance sheet as of December 31, 2017. In June 2018, the escrow agent will disburse to the Company the Escrow Amount less (i) that portion of the Escrow Amount previously paid in satisfaction of claims for indemnification pursuant to the terms of the Purchase Agreement and (ii) that portion of the Escrow Amount that is determined, in the reasonable judgment of Hitachi, to be necessary to satisfy all unsatisfied or disputed claims for indemnification specified in any claim notice delivered to the Company. The Company also received the $4.4 million Additional Consideration payment in July 2017. The Company incurred approximately $6.9 million in transaction costs related to the 2017 Hitachi Transaction, including $4.3 million in retention payments to PCT employees, of which 50% was paid in June 2017, and the other 50% payable on the one year anniversary of the closing date.

The Company recognized the following gain on the date of sale of its 80.1% interest in PCT (in thousands):



Fair value of consideration received	$	79,425
Transaction and retention costs	(6,919		)
Carrying value of segment non-controlling interest	3,687
	$	76,193
Less carrying amount of assets and liabilities sold:
Cash	$	6,727
Accounts receivable	3,702
Deferred costs	4,685
Prepaid expenses and other current assets	743
Property, plant and equipment, net	14,900
Goodwill	7,013
Intangibles, net	2,090
Other assets	215
Accounts payable	(2,278		)
Accrued liabilities	(2,927		)
Due from Caladrius	450
Unearned revenues	(10,529		)
Notes payable	(342		)
	$	24,449

Gain on sale of PCT	$	51,744

The operations and cash flows of the PCT Segment were eliminated from ongoing operations with the sale of the Company's PCT Interest. The operating results of the PCT Segment for the years ended December 31, 2017 and 2016 were as follows (in thousands):



	Year Ended December 31,
	2017			2016
Revenue	$	16,039		$	42,043
Cost of revenues	(15,321		)	(35,519		)
Research and development	(257		)	(800		)
Selling, general, and administrative	(3,251		)	(7,558		)
Other expense	(14		)	(80		)
Provision for income taxes	(10,541		)	(138		)
Gain on sale of segment	51,744			—
Income (loss) from discontinued operations	$	38,399		$	(2,052	)

Commitments and Contingencies

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Lease Commitments

We lease facilities under various operating lease agreements in Basking Ridge, NJ, Rye Brook, NY, and Irvine, CA, of which certain have escalation clauses and renewal options. We also lease equipment under certain noncancelable operating leases. Our leases expire from time to time through 2021.

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of December 31, 2017 are as follows (in thousands):



Years ended	Operating Leases
2018	910.0
2019	901.2
2020	827.0
2021	474.4
2022 and thereafter	128.6
Total minimum lease payments	$	3,241.2

Expense incurred under operating leases were approximately $1.4 million and $1.4 million for the years ended December 31, 2017 and 2016, respectively.

Contingencies

We have entered into a strategic collaboration with Sanford Research with the goal of developing a therapy for the treatment of T1D. The initial focus of the collaboration will be the execution of a prospective, randomized, placebo-controlled, double-blind clinical trial (The Sanford Project: T-Rex Study) to evaluate the safety and efficacy of the Company’s T regulatory cell product candidate, CLBS03, in adolescents with recent onset T1D. The Phase 2 study has an open and active IND in place and subject enrollment commenced in the first quarter of 2016. We were initially responsible for the supply of all study drug to the first 19 enrolled patients while Sanford assumed all patient and clinical site costs for subjects enrolled in their two centers as well as the expense associated with general clinical monitoring services. For the remaining 92 patients in the study, we will continue to be responsible for the supply of all study drug and the costs of study enrollment for sites outside of the Sanford centers.

Under license agreements with third parties the Company is typically required to pay maintenance fees, make milestone payments and/or pay other fees and expenses and pay royalties upon commercialization of products. The Company also sponsors research at various academic institutions, which research agreements generally provide us with an option to license new technology discovered during the course of the sponsored research.

From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Common Stock Sales Agreement On February 8, 2018, we entered into a Common Stock Sales Agreement with H.C. Wainwright & Co., LLC ("HCW"), as sales agent, in connection with an “at the market offering” under which we from time to time may offer and sell shares of our common stock, having an aggregate offering price of up to $12 million. Subject to the terms and conditions of the sales agreement, HCW will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares from time to time, based upon our instructions, including any price, time or size limits specified by us. We have provided HCW with customary indemnification rights, and HCW will be entitled to a commission at a fixed commission rate equal to 3.0% of the gross proceeds per share sold. We have no obligation to sell any of the shares, and may at any time suspend sales under the sales agreement or terminate the sales agreement. The sales agreement will terminate upon the sale of all of the shares under the sales agreement unless terminated earlier by either party as permitted under the sales agreement.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Cash and Cash Equivalents

Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.

Concentration of Risk

Concentration of Risks

Marketable Securities

Property, Plant and Equipment

Property, Plant, and Equipment



Furniture and fixtures	10 years
Computer equipment	3 years
Software	3 years
Leasehold improvements	Life of lease

Long-lived Assets

Share-Based Compensation

Income (Loss) Per Share

Income Taxes

Treasury Stock

Research and Development Costs

New Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Schedule of Property, Plant and Equipment



Furniture and fixtures	10 years
Computer equipment	3 years
Software	3 years
Leasehold improvements	Life of lease

Property, plant, and equipment consisted of the following (in thousands):



	December 31,
	2017			2016
Lab equipment	$	—		$	181.6
Furniture and fixtures	25.4			288.2
Computer equipment	998.3			1,173.4
Software	—			99.5
Leasehold improvements	65.6			115.7
Property, plant and equipment, gross	1,089.3			1,858.4
Accumulated depreciation	(832.4		)	(1,153.0		)
Property, plant and equipment, net	$	256.9		$	705.4

Available-for-Sale-Securities (Tables)

12 Months Ended

Dec. 31, 2017

Available-for-sale Securities [Abstract]

Schedule of Available-for-sale Securities Reconciliation [Table Text Block]

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents in our Consolidated Balance Sheets (in thousands):



	December 31, 2017									December 31, 2016
	Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value		Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Corporate debt securities	$	42,701.0	$	—	$	(28.0	)	$	42,673.0	$	—	$	—	$	—	$	—
Money market funds	9,211.5		—		—			9,211.5		4,426.8		—		—		4,426.8
Total	$	51,912.5	$	—	$	(28.0	)	$	51,884.5	$	4,426.8	$	—	$	—	$	4,426.8

Marketable Securities [Table Text Block]



	December 31, 2017		December 31, 2016
Cash and cash equivalents	$	25,967.8	$	4,426.8
Marketable securities	25,916.7		—
Total	$	51,884.5	$	4,426.8

Investments Classified by Contractual Maturity Date [Table Text Block]

The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):



	December 31, 2017
	Amortized Cost		Estimated Fair Value
Less than one year	$	51,912.5	$	51,884.5
Greater than one year	—		—
Total	$	51,912.5	$	51,884.5

Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment



Furniture and fixtures	10 years
Computer equipment	3 years
Software	3 years
Leasehold improvements	Life of lease

Property, plant, and equipment consisted of the following (in thousands):



	December 31,
	2017			2016
Lab equipment	$	—		$	181.6
Furniture and fixtures	25.4			288.2
Computer equipment	998.3			1,173.4
Software	—			99.5
Leasehold improvements	65.6			115.7
Property, plant and equipment, gross	1,089.3			1,858.4
Accumulated depreciation	(832.4		)	(1,153.0		)
Property, plant and equipment, net	$	256.9		$	705.4

Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Schedule of Potentially Dilutive Securities Excluded from Calculation of Loss Per Share

At December 31, 2017 and 2016 the Company excluded the following potentially dilutive securities:



	December 31,
	2017	2016
Stock Options	1,072,499	953,690
Warrants	209,818	388,062
Restricted Shares	181,908	126,849
Restricted Stock Units	10,260	—

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Schedule of Fair Value of Assets Measured on Recurring Basis

The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2017 and December 31, 2016 were as follows (in thousands):



	December 31, 2017								December 31, 2016
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Marketable securities - available for sale	$	—	$	25,916.7	$	—	$	25,916.7	$	—	$	—	$	—	$	—
	$	—	$	25,916.7	$	—	$	25,916.7	$	—	$	—	$	—	$	—

Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2017

Accrued Liabilities [Abstract]

Schedule of Accrued Liabilities

Accrued liabilities were as follow (in thousands):



	December 31,
	2017		2016
Salaries, employee benefits and related taxes	$	1,389.2	$	1,406.3
Retention payments	2,233.0		—
Professional fees	286.7		224.5
CIRM upfront funding - current	2,445.9		—
Other	1,456.1		1,028.6
	$	7,810.9	$	2,659.4

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan

The number of remaining shares authorized to be issued under the various equity plans are as follows as of December 31, 2017:



	2003 Equity Plan		2009 Equity Plan		2015 Equity Plan
Shares Authorized for Issuance	25,000		899,500		440,000
2016 Evergreen increase of shares	—		—		226,932
2017 Evergreen increase of shares					328,232
Outstanding Stock Options	(5,006	)	(432,916	)	(634,577	)
Exercised Stock Options	(925	)	(8,093	)	(3,835	)
Restricted stock or equity grants issued under Equity Plans	(8,922	)	(156,467	)	—
Shares Expired	(10,147	)	(302,024	)	(314,254	)
Total common shares remaining to be issued under the Equity Plans	—		—		42,498

Schedule of Share-based Compensation, Stock Options, Activity

The following table summarizes the activity for stock options and warrants for the year ended December 31, 2017:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2016	952,790		$	39.90	7.60	$	—	388,062		$	76.50	1.24	$	—

Changes during the Year:
Granted	448,057		$	11.70				—		$	—
Exercised	(3,835	)	$	4.70				—		$	—
Forfeited	(244,413	)	$	18.80				(1,937	)	$	700.00
Expired	(80,100	)	$	35.80				(176,307	)	$	103.90
Outstanding at December 31, 2017	1,072,499		$	33.50	4.76	$	0.1	209,818		$	53.20	0.95	$	—
Vested at December 31, 2017 or expected to vest in the future	1,072,107		$	33.5	4.76	$	0.1	209,818		$	53.20	0.95	$	—
Exercisable at December 31, 2017	1,063,759		$	32.9	4.77	$	0.1	209,818		$	53.20	0.95	$	—

The following table summarizes the components of share-based compensation expense for the years ended December 31, 2017 and 2016 ($ in thousands):



	Year Ended December 31,
	2017		2016
Research and development	$	268.9	$	262.3
General and administrative	1,694.3		1,511.5
Discontinued operations	888.9		830.6
Total share-based compensation expense	$	2,852.1	$	2,604.3

Restricted Stock

During the years ended December 31, 2017 and 2016, the Company issued restricted stock for services as follows ($ in thousands, except share data):




	2017		2016
Number of Restricted Stock Issued	181,908		126,849
Value of Restricted Stock Issued	$	627.7	$	698.1

Share-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity

The following table summarizes the activity for stock options and warrants for the year ended December 31, 2017:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2016	952,790		$	39.90	7.60	$	—	388,062		$	76.50	1.24	$	—

Changes during the Year:
Granted	448,057		$	11.70				—		$	—
Exercised	(3,835	)	$	4.70				—		$	—
Forfeited	(244,413	)	$	18.80				(1,937	)	$	700.00
Expired	(80,100	)	$	35.80				(176,307	)	$	103.90
Outstanding at December 31, 2017	1,072,499		$	33.50	4.76	$	0.1	209,818		$	53.20	0.95	$	—
Vested at December 31, 2017 or expected to vest in the future	1,072,107		$	33.5	4.76	$	0.1	209,818		$	53.20	0.95	$	—
Exercisable at December 31, 2017	1,063,759		$	32.9	4.77	$	0.1	209,818		$	53.20	0.95	$	—

The following table summarizes the components of share-based compensation expense for the years ended December 31, 2017 and 2016 ($ in thousands):



	Year Ended December 31,
	2017		2016
Research and development	$	268.9	$	262.3
General and administrative	1,694.3		1,511.5
Discontinued operations	888.9		830.6
Total share-based compensation expense	$	2,852.1	$	2,604.3

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]



	Stock Options		Restricted Stock
Unrecognized compensation cost	$	39.5	$	97.2
Expected weighted-average period in years of compensation cost to be recognized	0.61		1.84

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the years ended December 31, 2017 and 2016 were as follows ($ in thousands):



	Stock Options
	Year Ended December 31,
	2017		2016
Total fair value of shares vested	$	5,001.7	$	2,359.8
Weighted average estimated fair value of shares granted	1.72		3.23

Schedule of Range of Fair Value of Stock Options and Warrants

The range of assumptions made in calculating the fair values of stock options was as follow:



	Stock Options
	Year Ended December 31,
	2017	2016
Expected term - minimum (in years)	6	5
Expected term - maximum (in years)	6	10
Expected volatility - minimum	71%	73%
Expected volatility - maximum	74%	76%
Weighted Average volatility	35%	74%
Expected dividend yield	—	—
Risk-free interest rate - minimum	1.99%	1.07%
Risk-free interest rate - maximum	2.28%	2.19%

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Schedule of Income before Income Tax, Domestic and Foreign

The provision (benefit) for income taxes is based on loss from operations before provision for income taxes and noncontrolling interests as follows ($ in thousands):



	Years Ended December 31,
	2017			2016
United States	$	(27,698	)	$	(31,258	)
	$	(27,698	)	$	(31,258	)

Schedule of Components of Income Tax Expense (Benefit)

The provision (benefit) for income taxes was as follows ($ in thousands):



		Years Ended December 31,
		2017			2016
Current
	U.S. Federal	$	(9,310	)	$	—
	State and local	(1,641		)	—
		$	(10,951	)	$	—
Deferred
	U.S. Federal	$	(576	)	$	—
	State and local	—			—
		$	(576	)	$	—
Total
	U.S. Federal	$	(9,886	)	$	—
	State and local	(1,641		)	—
		$	(11,527	)	$	—

Schedule of Unrecognized Tax Benefits Roll Forward

The provision (benefit) for income taxes is determined by applying the U.S. Federal statutory rate of 34% to income before income taxes as a result of the following ($ in thousands):



	Years Ended December 31,
	2017			2016
U.S. Federal benefit at statutory rate	$	(9,417	)	$	(10,628	)
State and local (benefit) / expense net of U.S. federal tax	(1,641		)	2,759
Permanent non deductible expenses for U.S. taxes	107			80
AMT credit benefit	(576		)	—
True-up of prior year net operating loss	—			(2,371		)
Effect of change in deferred tax rate	29,809			(44		)
Valuation allowance for deferred tax assets	(29,809		)	10,204
Tax provision benefit	$	(11,527	)	$	—

Schedule of Deferred Tax Assets and Liabilities

Deferred income taxes at December 31, 2017 and 2016 consist of the following ($ in thousands):



	December 31,
	2017			2016
Deferred Tax Assets:
Accumulated net operating losses (tax effected)	$	60,171		$	79,131
CIRM funding	1,780			—
Deferred rent	3			314
Share-based compensation	2,656			11,562
Intangibles	270			429
Charitable contributions	11			424
Partnership interest	—			3,858
Capital loss carry-forward	—			6,988
Accumulated depreciation	22			—
Accrued payroll	682			—
AMT credit	575			—
Other	526			659
Deferred tax assets	66,696			103,365

Deferred Tax Liabilities:
Accumulated depreciation	$	—		$	(119	)
Deferred tax liabilities	—			(119		)
	66,696			103,246
Valuation allowance	(66,121		)	(103,246		)
Net deferred tax asset	$	575		$	—

Discontinued Operations (Tables)

12 Months Ended

Dec. 31, 2017

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Discontinued Operations

The Company recognized the following gain on the date of sale of its 80.1% interest in PCT (in thousands):



Fair value of consideration received	$	79,425
Transaction and retention costs	(6,919		)
Carrying value of segment non-controlling interest	3,687
	$	76,193
Less carrying amount of assets and liabilities sold:
Cash	$	6,727
Accounts receivable	3,702
Deferred costs	4,685
Prepaid expenses and other current assets	743
Property, plant and equipment, net	14,900
Goodwill	7,013
Intangibles, net	2,090
Other assets	215
Accounts payable	(2,278		)
Accrued liabilities	(2,927		)
Due from Caladrius	450
Unearned revenues	(10,529		)
Notes payable	(342		)
	$	24,449

Gain on sale of PCT	$	51,744



	Year Ended December 31,
	2017			2016
Revenue	$	16,039		$	42,043
Cost of revenues	(15,321		)	(35,519		)
Research and development	(257		)	(800		)
Selling, general, and administrative	(3,251		)	(7,558		)
Other expense	(14		)	(80		)
Provision for income taxes	(10,541		)	(138		)
Gain on sale of segment	51,744			—
Income (loss) from discontinued operations	$	38,399		$	(2,052	)

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=84176398&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84176398&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

+ Details

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of December 31, 2017 are as follows (in thousands):



Years ended	Operating Leases
2018	910.0
2019	901.2
2020	827.0
2021	474.4
2022 and thereafter	128.6
Total minimum lease payments	$	3,241.2

The Business - CLBS03 (Details) $ in Millions		1 Months Ended	3 Months Ended
The Business - CLBS03 (Details) $ in Millions	Jan. 18, 2018 patient	Oct. 31, 2016 patient	Mar. 31, 2016 cohort	May 04, 2017 USD ($)	Feb. 28, 2017 USD ($)	Feb. 23, 2017 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Grants Receivable \| $					$ 12.2	$ 12.2
Grants Receivable, Current \| $				$ 5.7
Number of patients enrolled \| patient		19
Interim efficacy analysis, percentage threshold			50.00%
Interim efficacy analysis, follow-up milestone period			6 years
The Sanford Project: T-Rex Study [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of cohorts (cohort) \| cohort			2
Subsequent Event [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of patients enrolled \| patient	110

The Business - Cell Therapy Development and Manufacturing (Details) - USD ($) $ in Millions		1 Months Ended
	Oct. 02, 2017	Dec. 31, 2017	May 31, 2017	Mar. 11, 2016
Subsidiary or Equity Method Investee [Line Items]
Revenue from grants	$ 1.9	$ 1.9	$ 5.7
Equity Method Investment, Ownership Percentage				19.90%
Hitachi America [Member]
Subsidiary or Equity Method Investee [Line Items]
Equity Method Investment, Ownership Percentage				21.00%

The Business - Principles of Consolidation (Details) - USD ($)		12 Months Ended
	May 18, 2017	Dec. 31, 2017	Dec. 31, 2016	Mar. 11, 2016
Subsidiary or Equity Method Investee [Line Items]
Equity Method Investment, Ownership Percentage				19.90%
Change in ownership in subsidiary		$ 0	$ 0
Hitachi America [Member]
Subsidiary or Equity Method Investee [Line Items]
Equity Method Investment, Ownership Percentage				21.00%
Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] \| PCT Segment [Member]
Subsidiary or Equity Method Investee [Line Items]
Subsidiary, Ownership Interest by Parent	80.10%
Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] \| PCT Segment [Member] \| PCT Allendale, LLC [Member] \| Hitachi America [Member]
Subsidiary or Equity Method Investee [Line Items]
Purchase Agreement, Aggregate Purchase Price	$ 75,000,000

Summary of Significant Accounting Policies (Details)	3 Months Ended	12 Months Ended
Summary of Significant Accounting Policies (Details)	Jun. 30, 2015 reporting_unit	Dec. 31, 2017	Dec. 31, 2016 USD ($) reporting_unit	Mar. 11, 2016 USD ($)
Property, Plant and Equipment [Line Items]
Number of reporting units (reporting_unit) \| reporting_unit	2		2
Impairment of intangible assets			$ 0
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives		P10Y
Computer equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives		P3Y
Software
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives		P3Y
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives		life of lease
PCT Allendale, LLC [Member]
Property, Plant and Equipment [Line Items]
Contract Receivable				$ 5,600,000

Collaboration and Hitachi License Agreement - 2016 Hitachi Transaction (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Mar. 31, 2016	Mar. 11, 2016
Business Acquisition [Line Items]
Equity Method Investment, Ownership Percentage			19.90%
Hitachi Chemical Co., LTD [Member]
Business Acquisition [Line Items]
Equity Method Investment, Ownership Percentage			21.00%
Recorded Unconditional Purchase Obligation		$ 20.5	$ 19.4
Unrecorded Unconditional Purchase Obligation, Maximum Quantity			15.0
PCT Allendale, LLC [Member]
Business Acquisition [Line Items]
Contract Receivable			$ 5.6
PCT Allendale, LLC [Member]
Business Acquisition [Line Items]
Purchase Obligation			$ 4.4
Minimum [Member] \| PCT Allendale, LLC [Member]
Business Acquisition [Line Items]
Length of Contract for Royalty Payments from Revenue Generated in Asia	10 years

Collaboration and Hitachi License Agreement - 2017 Hitachi Transaction (Details) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended	12 Months Ended
	May 18, 2017	Mar. 31, 2017	Sep. 30, 2017	May 18, 2018
PCT Segment [Member] \| Discontinued Operations [Member]
Business Acquisition [Line Items]
Subsidiary, Ownership Interest by Parent	80.10%
Transaction and retention costs	$ 6,919
Payments to Employees			$ 4,300
Payment for Retention Agreement in Connection with Sale, First Retention Payment, Percent			50.00%
Payment for Retention Agreement in Connection with Sale, Second Retention Payment, Percent			50.00%
Hitachi Chemical Co., LTD [Member] \| PCT Segment [Member] \| Discontinued Operations [Member]
Business Acquisition [Line Items]
Purchase Agreement, Additional Consideration	4,400
Purchase Agreement, Potential Future Milestone Payment	5,000
Cumulative Revenue Threshold for Receiving Milestone Payment	125,000
Proceeds From Licensing Agreements, Initial Payment		$ 5,000
Proceeds From Licensing Agreements, Closing Payments	65,000
Proceeds From Licensing Agreements, Escrow Amount	5,000
Hitachi Chemical Co., LTD [Member] \| PCT Allendale, LLC [Member] \| PCT Segment [Member] \| Discontinued Operations [Member]
Business Acquisition [Line Items]
Purchase Agreement, Aggregate Purchase Price	75,000
Director [Member] \| Robert A. Preti [Member]
Business Acquisition [Line Items]
Related Party Transaction, Payment for Retention Agreement in Connection with Sale, First Retention Payment	$ 1,900
Scenario, Forecast [Member] \| Director [Member] \| Robert A. Preti [Member]
Business Acquisition [Line Items]
Related Party Transaction, Payment for Retention Agreement in Connection with Sale, Second Retention Payment				$ 1,900
Related Party Transaction, Payment for Retention Agreement in Connection with Sale, Third Retention Payment, Percentage of Milestone Payment				5.00%

Available-for-Sale-Securities (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	$ 51,912,500	$ 4,426,800
Gross Unrealized Gains	0	0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	(28,000)	0
Fair Value, Estimate Not Practicable, Investments	51,884,500	4,426,800
Cash and cash equivalents	25,967,800	4,426,800
Available-for-sale Securities, Current	25,916,700	0
Cash, Cash Equivalents, and Short-term Investments	51,884,500	4,426,800
Available-for-sale Securities, Debt Maturities, Next Rolling Twelve Months, Amortized Cost Basis	51,912,500
Available-for-sale Securities, Debt Maturities, Next Rolling Twelve Months, Fair Value	51,884,500
Available-for-sale Securities, Debt Securities	51,884,500
Corporate Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	42,701,000	0
Gross Unrealized Gains	0	0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	(28,000)	0
Fair Value, Estimate Not Practicable, Investments	42,673,000	0
Money Market Funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	9,211,500	4,426,800
Gross Unrealized Gains	0	0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	0	0
Money Market Funds, at Carrying Value	$ 9,211,500	$ 4,426,800

Property, Plant and Equipment (Details) - USD ($)	12 Months Ended
Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment, Net, by Type [Abstract]
Property, plant and equipment, gross	$ 1,089,300	$ 1,858,400
Accumulated depreciation	(832,400)	(1,153,000)
Property, plant and equipment, net	256,905	705,438
Depreciation expense	400,000	500,000
Lab equipment
Property, Plant and Equipment, Net, by Type [Abstract]
Property, plant and equipment, gross	0	181,600
Furniture and fixtures
Property, Plant and Equipment, Net, by Type [Abstract]
Property, plant and equipment, gross	25,400	288,200
Computer equipment
Property, Plant and Equipment, Net, by Type [Abstract]
Property, plant and equipment, gross	998,300	1,173,400
Software
Property, Plant and Equipment, Net, by Type [Abstract]
Property, plant and equipment, gross	0	99,500
Leasehold improvements
Property, Plant and Equipment, Net, by Type [Abstract]
Property, plant and equipment, gross	$ 65,600	$ 115,700

Loss Per Share (Details) - shares	9 Months Ended		12 Months Ended
Loss Per Share (Details) - shares	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2017	Dec. 31, 2016
Stock Options [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares			1,072,499	953,690
Warrant [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares			209,818	388,062
Restricted Stock [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	10,260	0	181,908	126,849

Fair Value Measurements (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	$ 25,916,700	$ 0
Assets, Fair Value Disclosure	25,916,700	0
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Assets, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	25,916,700	0
Assets, Fair Value Disclosure	25,916,700	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Assets, Fair Value Disclosure	$ 0	$ 0

- Definition

Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.

+ References + Details

Accrued Liabilities (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Accrued Liabilities [Abstract]
Salaries, employee benefits and related taxes	$ 1,389,200	$ 1,406,300
Retention Payable	2,233,000	0
Professional fees	286,700	224,500
Grants Receivable, Current	2,445,900	0
Other	1,456,100	1,028,600
Accrued Liabilities	$ 7,810,900	$ 2,659,400

Debt (Details) - USD ($)			1 Months Ended	12 Months Ended
Debt (Details) - USD ($)	May 18, 2017	Mar. 11, 2016	Sep. 30, 2016	Dec. 31, 2017	Dec. 31, 2016	Sep. 30, 2017	Sep. 26, 2014
Debt Instrument [Line Items]
Notes Payable				$ 200,000	$ 700,000
Interest Expense				377,768	1,779,657
Loan and Security Agreement [Member]
Debt Instrument [Line Items]
Interest Expense				400,000	$ 1,700,000
Long-term Debt [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross							$ 15,000,000
Oxford Finance LLC [Member]
Debt Instrument [Line Items]
Repayments of debt		$ 7,000,000	$ 3,000,000
Long-term Debt				$ 5,700,000
Debt Instrument, Payment To Lender Based On Receipt Of Proceeds From Eligible Events, Percent		20.00%
Oxford Finance LLC [Member] \| Loans Payable [Member] \| Loan and Security Agreement [Member]
Debt Instrument [Line Items]
Repayments of debt	$ 4,900,000
Debt Instrument, Interest Rate, Effective Percentage						8.50%
Minimum [Member] \| Notes Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Term				1 year

Redeemable Securities - Non-Controlling Interests (Details) - USD ($)			12 Months Ended
	May 18, 2017	Mar. 11, 2016	Dec. 31, 2017	Mar. 31, 2016
Business Acquisition [Line Items]
Equity Method Investment, Ownership Percentage		19.90%
Conversion of redeemable securities			$ 19,400,000
Hitachi Chemical Co., LTD [Member]
Business Acquisition [Line Items]
Recorded Unconditional Purchase Obligation		$ 19,400,000		$ 20,500,000
Equity Method Investment, Ownership Percentage		21.00%
Business Combination, Consideration Transfered, Interest Rate		2.00%
Conversion of redeemable securities	$ 14,700,000
Redeemable Securities, Classified to Non-Controlling Interests	$ 4,700,000

Stockholders' Equity (Details)			1 Months Ended	12 Months Ended
Stockholders' Equity (Details)	Jul. 28, 2016	Mar. 10, 2016 USD ($) $ / shares shares	Nov. 30, 2015	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2015 shares	Oct. 06, 2014 shares	Oct. 03, 2013 shares	Dec. 31, 2012 shares	Oct. 10, 2012 shares	Oct. 14, 2011 shares	Jan. 18, 2011 shares	Jun. 02, 2010 shares	Oct. 29, 2009 shares	May 09, 2009 shares
Class of Stock [Line Items]
Stock Split, Conversion Ratio	0.1
Common stock, par value (USD per share) \| $ / shares				$ 0.001	$ 0.001
Common stock, shares, issued (shares)		141,844		9,483,911	8,205,790
Common Stock Warrants, Shares		141,844			388,062
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares		$ 10.00
Share Price \| $ / shares		$ 7.05
Proceeds from Issuance of Warrants \| $		$ 1,000,000
Common stock, shares authorized (shares)				500,000,000	500,000,000
Stock Issued During Period, Shares, Restricted Stock Award, Gross				181,908	126,849
Stock Issued During Period, Value, Restricted Stock Award, Gross \| $				$ 627,700	$ 698,100
Common Stock [Member]
Class of Stock [Line Items]
Shares, Outstanding				9,483,911	8,205,790	5,673,302
Stock Issued During Period, Shares, New Issues				1,219,741	2,418,144
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Shares, Issued				319,776
Term Of Agreement In Months			24 months
Minimum [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				1 year
Common Stock [Member]
Class of Stock [Line Items]
Common stock, par value (USD per share) \| $ / shares				$ 0.001
ESPP [Member]
Class of Stock [Line Items]
Number of shares authorized under the plan				100,000					50,000
Shares, Issued				21,924
Shares, Outstanding				32,530
Non US Equity Plan [Member] \| Stock Options [Member]
Class of Stock [Line Items]
Common stock, shares authorized (shares)										57,000
2009 Equity Plan [Member] \| Stock Options [Member]
Class of Stock [Line Items]
Common stock, shares authorized (shares)							899,500	599,500		45,000	237,500	177,500	137,500	97,500	38,000
US Equity Plan [Member] \| 2015 Equity Plan [Member] \| Stock Options [Member] \| 2015 Equity Plan [Member]
Class of Stock [Line Items]
Common stock, shares authorized (shares)				440,000
Common Stock, Shares Authorized, Period for Automatic Increase				10 years
Initial Reserve Or Shares, Percent Increase Each Year				4.00%
Initial Reserve, Increase In Number Of Shares Each Year				17,600
US Equity Plan [Member] \| 2009 Equity Plan [Member] \| Stock Options [Member] \| 2009 Equity Plan [Member]
Class of Stock [Line Items]
Common stock, shares authorized (shares)				899,500
Share-based Compensation Award, Tranche One [Member] \| Stock Options [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				2 years
Share-based Compensation Award, Tranche Two [Member] \| Stock Options [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				3 years
Share-based Compensation Award, Tranche Three [Member] \| Stock Options [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Restricted Stock [Member]
Class of Stock [Line Items]
weighted average estimated fair value of restricted stock \| $ / shares				$ 3.45	$ 5.50
Restricted Stock [Member] \| Maximum [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				4 years

Stockholders' Equity - Components of Share-Based Compensation Expense (Details) - shares	Dec. 31, 2017	Dec. 31, 2016	Oct. 06, 2014	Oct. 03, 2013	Oct. 10, 2012	Oct. 14, 2011	Jan. 18, 2011	Jun. 02, 2010	Oct. 29, 2009	May 09, 2009
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	(209,818)
Common stock, shares authorized (shares)	500,000,000	500,000,000
Common stock, shares, outstanding (shares)	9,483,911	8,205,790
Stock Options [Member] \| 2009 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized (shares)			899,500	599,500	45,000	237,500	177,500	137,500	97,500	38,000
Stock Options [Member] \| Non US Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized (shares)					57,000
2015 Equity Plan [Member] \| US Equity Plan [Member] \| Stock Options [Member] \| 2015 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	(3,835)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	0
Shares Expired	(314,254)
Common stock, shares authorized (shares)	440,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	(634,577)
Common stock, shares, outstanding (shares)	42,498
2009 Equity Plan [Member] \| US Equity Plan [Member] \| Stock Options [Member] \| 2009 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	(8,093)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	(156,467)
Shares Expired	(302,024)
Common stock, shares authorized (shares)	899,500
Common Stock, Capital Shares Reserved for Future Issuance	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	(432,916)
Common stock, shares, outstanding (shares)	0
2003 Equity Plan [Member] \| US Equity Plan [Member] \| Stock Options [Member] \| 2003 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	(925)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	(8,922)
Shares Expired	(10,147)
Common stock, shares authorized (shares)	25,000
Common Stock, Capital Shares Reserved for Future Issuance	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	(5,006)
Common stock, shares, outstanding (shares)	0
Evergreen 2016 [Member] \| 2015 Equity Plan [Member] \| US Equity Plan [Member] \| Stock Options [Member] \| 2015 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	226,932
Evergreen 2017 [Member] \| 2015 Equity Plan [Member] \| US Equity Plan [Member] \| Stock Options [Member] \| 2015 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	328,232

Stockholders' Equity - Activity for Stock Options and Warrants (Details)	12 Months Ended
	Dec. 31, 2017 USD ($) $ / shares $ / warrant shares	Dec. 31, 2016 USD ($) $ / shares $ / warrant shares	Mar. 10, 2016 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value \| $	$ 100
Common stock, shares, outstanding (shares)	9,483,911	8,205,790
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value \| $	$ 100	$ 0
Common Stock Warrants, Shares		388,062	141,844
Weighted Average Exercise Price, Warrants Outstanding \| $ / warrant	53.2	76.5
Weighted Average Remaining Contractual Term warrant outstanding	11 months 12 days
Weighted Average Remaining Contractual Term, Warrants Outstanding		1 year 2 months 27 days
Aggregate Intrinsic Value, Warrants Outstanding \| $	$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Outstanding [Roll Forward]
Warrants Granted	0
Weighted Average Exercise Price, Warrants Granted \| $ / shares	$ 0
Warrants Exercised	0
Weighted Average Exercise Price, Warrants Exercised \| $ / shares	$ 0
Warrants Expired	(1,937)
Weighted Average Exercise Price, Warrants Expired \| $ / shares	$ 700.0
Warrants Canceled	(176,307)
Weighted Average Exercise Price, Warrants Canceled \| $ / shares	$ 103.9
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value \| $	$ 100
shares, vested and expected to vest	209,818
Weighted Average Exercise Price, Warrants vested & expected to vest \| $ / warrant	53.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	209,818
Weighted Average Exercise Price, Warrants Exercisable \| $ / warrant	53.20
weighted Average Remaining Contractual Term, warrants vested	11 months 12 days
Aggregate Intrinsic Value, Warrants vested and expected to vest \| $	$ 0
Aggregate Intrinsic Value, Warrants vested \| $	$ 0
US Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price \| $ / shares	$ 33.5	$ 39.9
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	4 years 9 months 4 days	7 years 7 months 6 days
Common stock, shares, outstanding (shares)	209,818
Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest	11 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	1,072,107
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price \| $ / shares	$ 33.5
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	4 years 9 months 4 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	448,057
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares	$ 11.7
Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Outstanding [Roll Forward]
Stock Options, Outstanding at December 31, 2011	952,790
Stock Options Exercised	(3,835)
Stock Options Forfeited	(80,100)
Stock Options Expired	(244,413)
Stock Options, Outstanding at September 30, 2012	1,072,499	952,790
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price \| $ / shares	$ 35.8
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price \| $ / shares	18.8
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price \| $ / shares	$ 4.7
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	1,063,759
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price \| $ / shares	$ 32.9
Options, Vested, weighted Average Remaining Contractual Term	4 years 9 months 7 days

Stockholders' Equity - Compensation Cost Related to Nonvested Awards (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	181,908	126,849
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 627,700	$ 698,100
Restricted Stock [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
weighted average estimated fair value of restricted stock	$ 3.45	$ 5.50

Stockholders' Equity - Equity Plan (Details)	12 Months Ended
Stockholders' Equity - Equity Plan (Details)	Dec. 31, 2017 USD ($) offering_period shares	Dec. 31, 2016 shares	Oct. 06, 2014 shares	Oct. 03, 2013 shares	Oct. 10, 2012 shares	Oct. 14, 2011 shares	Jan. 18, 2011 shares	Jun. 02, 2010 shares	Oct. 29, 2009 shares	May 09, 2009 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized (shares)	500,000,000	500,000,000
Stock Options [Member] \| 2009 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized (shares)			899,500	599,500	45,000	237,500	177,500	137,500	97,500	38,000
Stock Options [Member] \| Non US Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized (shares)					57,000
ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Offering Periods, Employee Stock Purchase Plan \| offering_period	2
Offering Periods, Employee Stock Purchase Plan, Term	6 months
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	15.00%
ESPP annual cap \| $	$ 25,000
percentage of stock closing price	85.00%
percentage of ESPP closing price	85.00%
Shares, Issued	21,924
Shares, Outstanding	32,530
2015 Equity Plan [Member] \| US Equity Plan [Member] \| Stock Options [Member] \| 2015 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Expired	(314,254)
Common stock, shares authorized (shares)	440,000

Stockholders' Equity - Equity Issuances (Details)			1 Months Ended	12 Months Ended
Stockholders' Equity - Equity Issuances (Details)	Sep. 14, 2016 USD ($) clinical_trial_subject $ / shares shares	Mar. 10, 2016 USD ($) $ / shares shares	Nov. 30, 2015 USD ($) shares	Dec. 31, 2017 USD ($) shares	Dec. 31, 2016 shares
Class of Stock [Line Items]
Common stock, shares, issued (shares) \| shares		141,844		9,483,911	8,205,790
Common Stock Warrants, Shares \| shares		141,844			388,062
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares		$ 10.00
Share Price \| $ / shares		$ 7.05
Proceeds from Issuance of Warrants		$ 1,000,000
RD Purchase Agreement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues \| shares	847,458
Shares Issued, Price Per Share \| $ / shares	$ 4.72
Proceeds from Issuance of Common Stock	$ 4,000,000
Private Purchase Agreement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues \| shares				932,204
Purchase Commitment, Maximum Amount Committed, Shares \| shares	4,449,153
Proceeds from Issuance of Common Stock, Initial Closing	$ 12,600,000
Proceeds from Issuance of Common Stock, Second Closing	$ 8,400,000			$ 4,400,000
Number of Subjects, Phase 2 CLBS03 Clinical Trial, Second Closing \| clinical_trial_subject	70
Proceeds from Issuance of Common Stock, Initial Closing, Receivable				6,000,000
Proceeds from Issuance of Common Stock, Second Closing, Receivable				$ 4,000,000
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Purchase Commitment, Maximum Amount Committed, Shares \| shares			1,101,928
Purchase Commitment, Remaining Minimum Amount Committed			$ 30,000,000
Term Of Agreement In Months			24 months
Shares, Issued \| shares				319,776
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Fair Value of Shares				$ 1,500,000

Share-Based Compensation (Details)	12 Months Ended
Share-Based Compensation (Details)	Dec. 31, 2017 USD ($)
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 39,500
Excepted weighted-average period in years of compensation cost to be recognized	7 months 10 days
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 97,200
Excepted weighted-average period in years of compensation cost to be recognized	1 year 10 months 2 days

Share-Based Compensation - Narrative (Details) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost		$ 1,900,000
Allocated Share-based Compensation Expense			$ 2,852,100	$ 2,604,300
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost	$ 300,000
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense			268,900	262,300
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense			1,694,300	1,511,500
Discontinued Operations, Disposed of by Sale [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense			$ 888,900	$ 830,600
Stock Options [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price			$ 1.72	$ 3.23
Stock Option [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition			$ 5,001,700	$ 2,359,800
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum			71.00%	73.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum			74.00%	76.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate			0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum			1.99%	1.07%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum			2.28%	2.19%

Share-Based Compensation - Valuation Assumptions (Details) - Stock Option [Member]	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	71.00%	73.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	74.00%	76.00%
Fair Value Assumptions, Weighted Average Volatility Rate	35.00%	74.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	1.99%	1.07%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	2.28%	2.19%
Minimum [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Minimum	6 years	5 years
Maximum [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Minimum	6 years	10 years

Research Funding (Details) - USD ($) $ in Millions		1 Months Ended		12 Months Ended
Research Funding (Details) - USD ($) $ in Millions	Oct. 02, 2017	Dec. 31, 2017	May 31, 2017	Dec. 31, 2017	Feb. 28, 2017	Feb. 23, 2017
Deferred Revenue Arrangement [Line Items]
Grants receivable					$ 12.2	$ 12.2
Grant payments received	$ 1.9	$ 1.9	$ 5.7
Grant revenue recognized				$ 1.3
Accrued Liabilities
Deferred Revenue Arrangement [Line Items]
Deferred grant revenue		2.4		2.4
Other Long-term Liabilities
Deferred Revenue Arrangement [Line Items]
Deferred grant revenue		$ 3.9		$ 3.9

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Provisional income tax expense related to remeasurement of deferred taxes at newly enacted tax rate	$ 30,000,000
Tax Adjustments, Settlements, and Unusual Provisions	(27,698,000)
Loss before benefit from income taxes and noncontrolling interests	(27,697,706)	$ (31,257,751)
Current Federal Tax Expense (Benefit)	(9,310,000)	0
Current State and Local Tax Expense (Benefit)	(1,641,000)	0
Current Income Tax Expense (Benefit)	(10,951,000)	0
Deferred Federal Income Tax Expense (Benefit)	(576,000)	0
Deferred State and Local Income Tax Expense (Benefit)	0	0
Deferred Income Tax Expense (Benefit)	(576,000)	0
Federal Income Tax Expense (Benefit), Continuing Operations	(9,886,000)	0
State and Local Income Tax Expense (Benefit), Continuing Operations	(1,641,000)	0
Income Tax Expense (Benefit)	$ (11,526,557)	0
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	34.00%
Income Tax Reconciliation, Income Tax Expense (Benefit), at Federal Statutory Income Tax Rate	$ (9,417,000)	(10,628,000)
Income Tax Reconciliation, State and Local Income Taxes	(1,641,000)	2,759,000
Permanent non deductible expenses for U.S. taxes	107,000	80,000
Defined Benefit Plan, Other Cost (Credit)	(576,000)
Restatement of Prior Year Income, Net of Tax	0	2,371,000
Income Tax Reconciliation, Change in Enacted Tax Rate	29,809,000	(44,000)
Deferred Tax Assets, Valuation Allowance	(29,809,000)	10,204,000
Unrecognized Tax Benefits Resulting in Net Operating Loss Carryforward	60,171,000	79,131,000
Deferred Tax Assets, Deferred Income	1,780,000	0
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities	3,000	314,000
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost	2,656,000	11,562,000
Deferred Tax Assets, Goodwill and Intangible Assets	270,000	429,000
Deferred Tax Assets, Charitable Contribution Carryforwards	11,000	424,000
Deferred Tax Asset, Partnership Interest	0	3,858,000
Deferred Tax Assets, Capital Loss Carryforwards	0	6,988,000
Deferred Tax Assets, Accumulated Depreciation	22,000	0
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation	682,000	0
Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax	575,000	0
Deferred Tax Assets, Tax Credit Carryforwards, Other	526,000	659,000
Deferred Tax Assets, Net	66,696,000	103,365,000
Deferred Tax Liabilities Accumulated depreciation	0	(119,000)
Deferred Tax Liabilities, Gross	0	(119,000)
Deferred Tax Assets (Liabilities), Net	66,696,000	103,246,000
Valuation allowance	(66,121,000)	(103,246,000)
Deferred Income Tax Assets, Net	575,055	0
Operating Loss Carryforwards	$ 210,300,000	$ 232,700,000

Discontinued Operations - PCT Segment Narrative (Details) - PCT Segment [Member] - Discontinued Operations [Member] - USD ($) $ in Thousands		1 Months Ended	3 Months Ended
	May 18, 2017	Mar. 31, 2017	Sep. 30, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Subsidiary, Ownership Interest by Parent	80.10%
Transaction and retention costs	$ 6,919
Payments to Employees			$ 4,300
Payment for Retention Agreement in Connection with Sale, First Retention Payment, Percent			50.00%
Payment for Retention Agreement in Connection with Sale, Second Retention Payment, Percent			50.00%
Hitachi Chemical Co., LTD [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase Agreement, Additional Consideration	4,400
Purchase Agreement, Potential Future Milestone Payment	5,000
Cumulative Revenue Threshold for Receiving Milestone Payment	125,000
Proceeds From Licensing Agreements, Initial Payment		$ 5,000
Proceeds From Licensing Agreements, Closing Payments	65,000
Proceeds From Licensing Agreements, Escrow Amount	$ 5,000

Discontinued Operations - Gain on Sale of PCT Segment (Details) - PCT Segment [Member] - Discontinued Operations [Member] - USD ($) $ in Thousands		12 Months Ended
	May 18, 2017	Dec. 31, 2017	Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Fair value of consideration received	$ 79,425
Transaction and retention costs	6,919
Carrying value of segment non-controlling interest	3,687
Total consideration net of transaction costs and adjustments	76,193
Less carrying amount of assets and liabilities sold:
Cash	6,727
Accounts receivable	3,702
Deferred costs	4,685
Prepaid expenses and other current assets	743
Property, plant and equipment, net	14,900
Goodwill	7,013
Intangibles, net	2,090
Other assets	215
Accounts payable	2,278
Accrued liabilities	2,927
Due from Caladrius	450
Unearned revenues	10,529
Notes payable	342
Disposal group, including discontinued operation, net assets	24,449
Gain on sale of PCT	$ 51,744	$ 51,744	$ 0

Discontinued Operations - Operating Results of PCT Segment (Details) - USD ($)		12 Months Ended
	May 18, 2017	Dec. 31, 2017	Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income (loss) from discontinued operations		$ 38,399,236	$ (2,051,782)
PCT Segment [Member] \| Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue		16,039,000	42,043,000
Cost of revenues		(15,321,000)	(35,519,000)
Research and development		(257,000)	(800,000)
Selling, general, and administrative		(3,251,000)	(7,558,000)
Other expense		(14,000)	(80,000)
Provision for income taxes		(10,541,000)	(138,000)
Gain on sale of segment	$ 51,744,000	51,744,000	0
Income (loss) from discontinued operations		$ 38,399,000	$ (2,052,000)

Commitments and Contingencies (Details)	1 Months Ended	12 Months Ended
Commitments and Contingencies (Details)	Oct. 31, 2016 patient	Dec. 31, 2017 USD ($) patient	Dec. 31, 2016 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Number of patients enrolled \| patient	19
Number of patients still active in study \| patient		92
Operating Leases, Future Minimum Payments Due [Abstract]
2018		$ 910,000
2019		901,200
2020		827,000
2021		474,400
2022 and thereafter		128,600
Total minimum lease payments		3,241,200
Operating leases expenses		$ 1,400,000	$ 1,400,000

Subsequent Events (Details) - Subsequent Event [Member] $ in Millions	Feb. 08, 2018 USD ($)
Subsequent Event [Line Items]
Aggregate offering price of shares authorized for sale per agreement	$ 12
Commission due to HCW upon gross proceeds of sale of stock (percent)	3.00%